Recombinant BST2 Protein, Human (His Tag) Recombinant Proteins The human BST2 (Q10589) (Asn49-Ser160) was expressed, with an N-terminal polyhistidine tag The recombinant human BST2 comprises 132a.a and has a predicted molecular weight of 14.9 kDa. The apparent molecular weight of the protein is approximately 23-26 kDa in SDS-PAGE under reducing conditions due to glycosylation.
$ $99 In stock
Formulation: The recombinant human BST2 comprises 132a.a and has a predicted molecular weight of 14.9 kDa. The apparent molecular weight of the protein is approximately 23-26 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Source: HEK293 Cells
Usage: Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use

Recombinant BST2 Protein, Human (His Tag)

Formulation: Recombinant BST2 Protein was lyophilized from sterile PBS, pH 7.41

Source: HEK293 Cells

Product Name Recombinant BST2 Protein, Human (His Tag)
Product Type Recombinant Protein
Source HEK293 Cells
Formulation Recombinant BST2 Protein was lyophilized from sterile PBS, pH 7.41
Molecular Weight The recombinant human BST2 comprises 132a.a and has a predicted molecular weight of 14.9 kDa. The apparent molecular weight of the protein is approximately 23-26 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Purity Greater than 95% as determined by SDS-PAGE
Description The human BST2 (Q10589) (Asn49-Ser160) was expressed, with an N-terminal polyhistidine tag
Host Species Homo sapiens (Human)
Usage Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Storage Store recombinant protein under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
AA Sequence Asn49-Ser160
Product Background BST2 was frequently overexpressed in GC tissues compared with the adjacent non-tumorous tissues, and high BST2 expression was correlated with tumor stage and lymphatic metastasis. Furthermore, in vitro experiments demonstrated that knockdown of BST2 by siRNA inhibited cell proliferation, induced apoptosis and repressed cell motility in GC cells. In addition, the pro-tumor function of BST2 in GC was mediated partly through the NF-κB signaling. BST2 possesses the oncogenic potential in GC by regulating the proliferation, apoptosis, and migratory ability of GC cells, thereby BST2 could be a potential therapeutic target for the treatment of GC. IFN (interferon)-induced BST2 recruits the E3 ubiquitin ligase MARCH8 to catalyze the K27-linked ubiquitination of MAVS for CALCOCO2-directed autophagic degradation, hence inhibiting DDX58-mediated type I interferon signaling through a negative feedback loop. BST2 is a host protein with dual functions in response to viral infections: it traps newly assembled enveloped virions at the plasma membrane in infected cells, and it induces NF-κB activity, especially in the context of retroviral assembly. BST2 may induce or amplify proinflammatory signaling during Ebola virus infection, potentially contributing to the dysregulated cytokine response that is a hallmark of Ebola virus disease.
Memo CD317 Protein, Human;TETHERIN Protein, Human
Uniprot Number Q10589
Terminal His
Bioactivity Please contact us for detailed information